U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

Pfizer ( PFE -1.29%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.

Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE announced late Monday a license agreement with China-based 3SBio Inc. HK:1530 to develop ...

The acquisition of SSGJ-707 coincides with Pfizer and Summit collaborating on ... stated that no changes are expected when asked how the 3SBio deal would impact its partnership with Summit.

Pfizer decided to think bigger and to in-license SSGJ-707 from 3SBio. The deal allows increased ... much lower financial risks than an outright acquisition of a company like Summit.

Recently, BioNTech SE announced an $800 million acquisition of Biotheus ... subject to customary regulatory approvals and 3SBio shareholder consent. Upon completion, Pfizer will also make a $100 ...

The drug Pfizer is licensing comes from Shenyang, China-based 3SBio. Under deal terms announced earlier this week, Pfizer is paying $1.25 billion up front for global rights to the biologic ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to ...

19, Pfizer announced it was entering into a licensing agreement with 3SBio, a China-based biotech ... particularly thanks to its $43 billion acquisition of the smaller cancer specialist Seagen.

Bernstein Reaffirms Pfizer Rating After $6B Cancer Treatment Deal The acquisition of SSGJ-707 coincides ... changes are expected when asked how the 3SBio deal would impact its partnership with ...